Literature DB >> 28786218

Response to "Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4*22 to Metabolism of Voriconazole".

Thomas J Walsh1, Brad Moriyama2, Scott R Penzak3, Teri E Klein4, Kelly E Caudle5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28786218     DOI： 10.1002/cpt.811

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  4 in total

Review 1.  Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.

Authors:  Alice J Hsu; Pranita D Tamma; Brian T Fisher
Journal:  Antimicrob Agents Chemother       Date:  2022-06-29       Impact factor: 5.938

2.  Integrating anatomo-physiological changes and pharmacogenomics in anti-infective therapy management: is it a major concern?

Authors:  Laura Beaumier; Sébastien Chanoine; Elodie Gautier-Veyret; Hélène Pluchart; Muriel Cornet; Marie-Pierre Brenier-Pinchart; Xavier Fonrose; Boubou Camara; Pierrick Bedouch
Journal:  Br J Clin Pharmacol       Date:  2018-11-16       Impact factor: 4.335

3.  Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients.

Authors:  Antonio C Arrieta; Michael Neely; J Christopher Day; Susan R Rheingold; Paul K Sue; William J Muller; Lara A Danziger-Isakov; Julie Chu; Inci Yildirim; Grace A McComsey; Haydar A Frangoul; Tempe K Chen; Victoria A Statler; William J Steinbach; Dwight E Yin; Kamal Hamed; Mark E Jones; Christopher Lademacher; Amit Desai; Kelley Micklus; Desiree Leiva Phillips; Laura L Kovanda; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

4.  Pharmacogenetic-Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017.

Authors:  Marc Maliepaard; Timi Toiviainen; Marie L De Bruin; Didier Meulendijks
Journal:  Clin Pharmacol Ther       Date:  2020-04-23       Impact factor: 6.875
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.